Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review

被引：2
|
作者：
Zheng, Ang [1 ]
Zhang, Lin [2 ]
Ji, Ziyao [3 ]
Fan, Lijuan [1 ]
Jin, Feng [1 ]
机构：
[1] China Med Univ, Affiliated Hosp 1, Dept Breast Surg, 155 Nanjing Rd, Shenyang 110001, Liaoning, Peoples R China
[2] Univ Chinese Acad Sci, NingBo Huamei Hosp, Beijing, Peoples R China
[3] China Med Univ, Affiliated Hosp 1, Dept Ultrasound, Shenyang, Liaoning, Peoples R China
来源：
AMERICAN JOURNAL OF MENS HEALTH | 2019年 / 13卷 / 03期
基金：
中国国家自然科学基金;
关键词：
male breast cancer; oncotype DX; endocrine therapy; treatment; GENE-EXPRESSION; TAMOXIFEN; RECURRENCE; PREDICTION; MANAGEMENT; PROGNOSIS; ASSAY;
D O I：
10.1177/1557988319847856
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Male breast cancer (MBC) is uncommon in clinical practice. Using the 21-gene assay to facilitate decision-making on comprehensive treatment of MBC is rarely reported. This study reports the case of a 53-year-old man with left breast cancer. Modified radical mastectomy was performed. Endocrine treatment was chosen for the patient according to the result of the 21-gene assay, a recommended genomic test of breast cancer. The patient remained in good health without evidence of recurrence at 18-month follow-up. This case provides a reference mode for the comprehensive management of early-stage, estrogen receptor-expressing and lymph node-negative MBC patients.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Impact of Oncotype DX testing on ER plus breast cancer treatment and survival in the first decade of use
    Schaafsma, Evelien
    Zhang, Baoyi
    Schaafsma, Merit
    Tong, Chun-Yip
    Zhang, Lanjing
    Cheng, Chao
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [2] Relationship of histologic grade and histologic subtype with oncotype Dx recurrence scoreI3/4 retrospective review of 863 breast cancer oncotype Dx results
    Singh, Kamaljeet
    He, Xin
    Kalife, Elizabeth T.
    Ehdaivand, Shahrzad
    Wang, Yihong
    Sung, C. James
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 29 - 34
  • [3] How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
    Zhu, Xiaofu
    Dent, Susan
    Paquet, Lise
    Zhang, Tinghua
    Tesolin, Daniel
    Graham, Nadine
    Aseyev, Olexiy
    Song, Xinni
    CURRENT ONCOLOGY, 2021, 28 (01) : 800 - 812
  • [4] Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation
    Biroschak, Julianne R.
    Schwartz, Gordon F.
    Palazzo, Juan P.
    Toll, Adam D.
    Brill, Kristin L.
    Jaslow, Rebecca J.
    Lee, Sun Yong
    BREAST JOURNAL, 2013, 19 (03) : 269 - 275
  • [5] Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
    Fried, Georgeta
    Moskovitz, Mor
    SPRINGERPLUS, 2014, 3 : 1 - 8
  • [6] Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
    Sengupta, Aditya K.
    Gunda, Aparna
    Malpani, Sukriti
    Serkad, Chandra Prakash, V
    Basavaraj, Chetana
    Bapat, Ashok
    Bakre, Manjiri M.
    CANCER MEDICINE, 2020, 9 (21): : 7810 - 7818
  • [7] Genomic signature in breast cancer: Oncotype DX®
    Teig, Benjamin
    ANNALES DE PATHOLOGIE, 2013, 33 (03) : 225 - 228
  • [8] Current controversies in the use of Oncotype DX in early breast cancer
    Giachetti, Pier Paolo M. Berton
    Schianca, Ambra Carnevale
    Trapani, Dario
    Marra, Antonio
    Toss, Angela
    Marchio, Caterina
    Dieci, Maria Vittoria
    Gentilini, Oreste Davide
    Criscitiello, Carmen
    Kalinsky, Kevin
    Sparano, Joseph A.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2025, 135
  • [9] Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
    Losk, Katya
    Freedman, Rachel A.
    Laws, Alison
    Kantor, Olga
    Mittendorf, Elizabeth A.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    Lin, Nancy U.
    Winer, Eric P.
    King, Tari A.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 215 - 227
  • [10] Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer
    de Lima, Mariana A. G.
    Clemons, Mark
    Van Katwyk, Sasha
    Stober, Carol
    Robertson, Susan J.
    Vandermeer, Lisa
    Fergusson, Dean
    Thavorn, Kednapa
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2020, 26 (03) : 889 - 892
12345